Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240015/S001

Womed Leaf

Womed Sas · Decision date Jan 28, 2026

FDA DECISIONP240015/S001

What did the FDA decide?

FDA records P240015/S001 as a supplement to PMA P240015, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 28, 2026.

FDA approval order statement

to add surface treatment and outsource the bonding process of the outer handle of the inserter and move to a semi-automated process for cutting and assembly
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Obstetrics/Gynecology
Decision date
Jan 28, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P240015/S001
Regulatory pathway
PMA supplement
Applicant
Womed Sas
Product code
MCN
Decision code
OK30
Decision date
Jan 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Barrier, absorbable, adhesion.

Applicant
Womed Sas
Product code
MCN
FDA device class
3

For the original device and its historical approval scope, see PMA P240015. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240015 · Original PMA

    Womed Leaf Resorbable Adhesion Barrier

  2. P240015/S001 received

    Application receipt date recorded by FDA.

  3. P240015/S001 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P240015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240015

Product / regulatory recordCompanyPathwayDecision dateSource
Womed SasPMA approvalSep 9, 2025FDA
Womed LeafP240015/S002
Womed SasPMA supplementAug 31, 2026FDA
Womed LeafP240015/S003
Womed SasPMA supplementOct 25, 2026FDA

Explore the linked device profile

Other records with product code MCN

Product / regulatory recordCompanyPathwayDecision dateSource
ETHICON, Inc.PMA supplementNov 5, 2026FDA
Rejoni, Inc.PMA supplementOct 28, 2026FDA
Rejoni, Inc.PMA approvalSep 28, 2026FDA
ETHICON, Inc.PMA supplementJun 25, 2026FDA
ETHICON, Inc.PMA supplementJan 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Womed Sas

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Batiment Balard Cit, 1919 Rte. De Mende, Montpellier, 34090

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records